Answers are grounded in this paper and cite their sources.
The most recently developed initial treatment regimens for chronic lymphocytic leukemia (CLL) are fixed-duration combinations of an inhibitor of Bruton tyrosine kinase (BTKi) and a B-cell lymphoma ...
No takes yet. Share an insight, caveat, or question.
Rogers et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: